| Objective: To study the role of PAX2 and C-MYC in the development of endometrial carcinoma,for further analyzing the relationship between the expressions of PAX2 /C-MYC and clinicopathologic parameters in endometrial carcinoma,and to provide a new idea for elucidating the mechanism of endometrial carcinogenesis and the early diagnosis and treatment.Methods: 60 cases of excising endometrial carcinoma tissues,35 cases of atypical hyperplastic tissues,and 35 cases of normal endometrial tissues from Octorber,2014 to Octorber,2016 in Affiliated Hospital of Youjiang Medical College For Nationalities and Attached Hechi hospital were collected.Immunohistochemistry(IHC)was employed to test protein expressions of PAX2 and C-MYC in those three different endometrial tissues.Then,30 samples of endometrial carcinoma tissues,12 samples of atypical hyperplastic tissues and15 samples of normal endometrial tissues were selected from the above fresh tissues.Besides,Quantitative Real-time PCR(Q-PCR)was used to examine the expressions of PAX2 and C-MYC mRNA in endometrial carcinoma tissues,atypical hyperplastic tissues and normal endometrial tissues.All data were analyzed by SPSS17 with P<0.05 considered statistical significance.Results:(1)IHC: The positive expression rates of PAX2 in normal endometrial tissues,atypical hyperplastic tissues and endometrial carcinoma tissues were 74.29%,48.57%,43.3% respectively,which showed statistical significance(P<0.05).The positive rate of PAX2 in normal endometrial tissues was higher than those in atypical hyperplastic tissues(P<0.05)and endometrial carcinoma tissues(P<0.01).The positive rate of PAX2 inendometrial carcinoma tissues was lower than that in atypical hyperplastic tissues,which had no statistical significance(P > 0.05).The protein expression of PAX2 was relevant to pathologic differentiation grades(P<0.05)and myometrial invasion(P<0.05)of endometrial carcinoma tissues while irrelevant to metastases of lymph node,clinical staging,ages and types of pathology(P > 0.05).The positive expression rates of C-MYC protein in normal endometrial tissues,atypical hyperplastic tissues and endometrial carcinoma tissues were17.14%,40.0%,66.67% respectively,which had statistical significance(P < 0.05).The positive rate of C-MYC protein in endometrial carcinoma tissues was higher than those in normal endometrial tissues(P < 0.01)and atypical hyperplastic tissues.(P < 0.05).The positive rate of C-MYC protein in atypical hyperplastic tissues was higher than that in normal endometrial tissues(P<0.01).C-MYC protein expression was closely related to pathologic differentiation grades(P< 0.05)and surgical-clinical staging(P < 0.05)of patients with endometrial carcinoma while unrelated to myometrial invasion,metastases of lymph node,ages and types of pathology(P>0.05).(2)Q-PCR: The expressions of PAX2 mRNA varied in different endometrial tissues(P < 0.001).The expression level of PAX2 mRNA in endometrial carcinoma tissues was lower than that in normal endometrial tissues(P<0.01).The expression level of PAX2 mRNA in atypical hyperplastic tissues was lower than that in normal endometrial tissues(P<0.01).The expression level of PAX2 mRNA in endometrial carcinoma tissues was lower than that in atypical hyperplastic tissues(P > 0.05).The expressions of C-MYC mRNA varied in different endometrial tissues(P < 0.01)..The expression of C-MYC mRNA in normal endometrial tissues was higher than those in endometrial carcinoma tissues(P < 0.01)and atypical hyperplastic tissues(P <0.01).The mRNA expression in endometrial carcinoma tissues was higher than that in atypical hyperplastic tissues(P<0.01).Conclusions:(1)The expressions of PAX2 in atypical hyperplastic tissues and endometrial carcinoma tissues are lower than that in normal endometrial tissues.The decreaseof them is likely to be the early lesions.(2)The increase in the expression of C-MYC in normal endometrial tissues,atypical hyperplastic tissues and endometrial carcinoma tissues may trigger the development of endometrial carcinoma.C-MYC probably becomes potentially diagnostic and therapeutic targets for endometrial carcinoma. |
PDF Full Text Request